Celularity To Present Data Showing Senescent Cell Elimination By Off-The-Shelf Natural Killer Cells Derived From Human Placental Cells
Celularity To Present Data Showing Senescent Cell Elimination By Off-The-Shelf Natural Killer Cells Derived From Human Placental Cells
"Celularity believes in the broad, but so far underrealized, potential of cell therapies. We continue to investigate cellular immunotherapy in age-related diseases, and these data are an important, continued step in demonstrating how our therapeutic assets may be used to eliminate senescent cells," said Celularity's CEO and Founder Dr. Robert Hariri, M.D., Ph.D. "Removing these aging, senescent cells, which we have termed 'senoablation,' may represent an important clinical approach to address the high societal cost of age-associated diseases and disabilities."Celularity Inc. (NASDAQ:CELU) ("Celularity"), a biotechnology company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that it will present in vitro data from its investigational natural killer (NK) cell therapy programs at this year's American Society of Gene and Cell Therapy (ASGCT) Annual Meeting. The preclinical data, which suggest that Celularity's placenta-derived unmodified natural killer (NK) cells (CYNK-001) and genetically modified NK cells (CYNK-201) may serve as potent and selective senolytic agents for use in addressing age-related diseases, will be presented on May 9, 2024.
开发胎盘衍生异基因细胞疗法和先进生物材料产品的生物技术公司Celularity Inc.（纳斯达克股票代码：CelU）（“Celularity”）今天宣布，将在今年的美国基因与细胞疗法学会（ASGCT）年会上公布其研究性自然杀伤（NK）细胞疗法项目的体外数据。临床前数据将于2024年5月9日发布，这些数据表明，Celularity的胎盘衍生未经改良的自然杀伤（NK）细胞（CYNK-001）和转基因NK细胞（CYNK-201）可以作为强效的选择性溶解剂，用于治疗与年龄相关的疾病。
Senescent cells are key drivers in the process of age-related cellular corruption at the heart of degenerative diseases, cancer and immuno-senescence (the progressive decline in immune function that occurs with age). These cells are unique in that they eventually stop multiplying but do not die; instead, they transform into the senescence associated secretory phenotype (SASP) and continue to release chemicals that can promote inflammation and tumor progression. Moreover, if not eliminated, these cells impair the normal regenerative process that restores function to organs and tissues.
衰老细胞是退行性疾病、癌症和免疫衰老（免疫功能随着年龄的增长而逐渐下降）的核心，衰老细胞是与年龄相关的细胞腐蚀过程的关键驱动因素。这些细胞的独特之处在于它们最终停止繁殖但不会死亡；相反，它们转化为衰老相关分泌表型（SASP），并继续释放可促进炎症和肿瘤进展的化学物质。此外，如果不消除，这些细胞会损害恢复器官和组织功能的正常再生过程。
Celularity is building a broad technology platform that leverages the placenta's unique immunobiology as a source of highly expandable, off-the-shelf cells, as well as a diverse portfolio of cell therapy investigational products to address age-related diseases, including cancer and degenerative diseases. Celularity believes these preclinical data demonstrate the potential of its assets to target and selectively remove damaged and abnormal cells expressing stress ligands, such as senescent, virally infected and cancer cells.
Celularity正在建立一个广泛的技术平台，该平台利用胎盘独特的免疫生物学作为高度可扩展的现成细胞的来源，以及多样化的细胞疗法研究产品组合，以解决与年龄相关的疾病，包括癌症和退行性疾病。Celularity认为，这些临床前数据表明，其资产有可能靶向和选择性地去除表达压力配体的受损和异常细胞，例如衰老细胞、病毒感染细胞和癌细胞。
"Celularity believes in the broad, but so far underrealized, potential of cell therapies. We continue to investigate cellular immunotherapy in age-related diseases, and these data are an important, continued step in demonstrating how our therapeutic assets may be used to eliminate senescent cells," said Celularity's CEO and Founder Dr. Robert Hariri, M.D., Ph.D. "Removing these aging, senescent cells, which we have termed 'senoablation,' may represent an important clinical approach to address the high societal cost of age-associated diseases and disabilities."
“Celularity相信细胞疗法具有广泛但迄今尚未实现的潜力。我们将继续研究年龄相关疾病的细胞免疫疗法，这些数据是证明我们的治疗资产如何用于消灭衰老细胞的重要而持续的一步，” Celularity首席执行官兼创始人罗伯特·哈里里博士说，“去除这些衰老的衰老细胞，我们称之为'去除'，可能是解决年龄相关疾病高昂社会成本的重要临床方法和残疾。”
The ASGCT Annual Meeting will take place on May 7 through 11, 2024, in Baltimore, Md.
ASGCT年会将于2024年5月7日至11日在马里兰州巴尔的摩举行。